HONG KONG – U.S.-based Tocagen Inc. granted Apollobio Corp., of Beijing, an exclusive license to develop and commercialize its immunotherapy for brain tumors in the greater China region. The license is expected to take effect in the second quarter.

HONG KONG – U.S.-based Tocagen Inc. granted Apollobio Corp., of Beijing, an exclusive license to develop and commercialize its immunotherapy for brain tumors in the greater China region. The license is expected to take effect in the second quarter.

HONG KONG – South Korean company Daewoong Pharmaceutical Co. Ltd. is partnering with Universitas Indonesia (UI), a state university in Jakarta, to jointly develop new biological medicines. The collaboration – the first of its kind in Indonesia – is expected to help Daewoong expand its global manufacturing and R&D network.

HONG KONG – China's Suzhou Alphamab Co. Ltd. has obtained the IND approval from regulators for its HER2 bispecific antibody, KN-026. The phase I trials will commence later this year.

HONG KONG – The Central Drugs Standard Control Organization (CDSCO) of India is setting up a national database, known as Sugam, of pharmaceutical manufacturers and their medicines to help address drug shortages and quality issues.

HONG KONG – China' Luye Pharma Group Ltd. said its investigational drug with billion-dollar potential, rotigotine extended-release microspheres for injection (LY-03003), was granted the regulatory approval to enter phase III trials in China.

HONG KONG – The Central Drugs Standard Control Organization (CDSCO) of India is setting up a national database, known as Sugam, of pharmaceutical manufacturers and their medicines to help address drug shortages and quality issues.